All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-10T08:43:13.000Z

EHA 2024 top abstracts: What’s hot in AML?

Jun 10, 2024
Share:

To help navigate the exciting content being presented at the European Hematology Association 2024 Hybrid Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.

Friday, June 14


Saturday, June 15

S135

11:30–11:45

Venetoclax-based salvage treatment for relapsed/refractory AML using a combination with high-dose cytarabine and mitoxantrone (HAM-VEN): Updated results of the phase-I/II SAL RELAX trial

Leo Ruhnke

S136

11:45–12:00

FLAG-IDA + venetoclax (VEN) in newly diagnosed (ND) or relapsed/refractory (RR) AML

Wei-Ying Jen

S138

12:15–12:30

Magrolimab vs placebo in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy: The ENHANCE-3 study

Naval Daver

S139

12:30–12:45

Phase 1/2 study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia

Alex Bataller

S102

15:15–15:30

First results of the APOLLO trial: A randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia

Uwe Platzbecker

S141

16:45–17:00

A post hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes who received oral azacitidine maintenance therapy in the QUAZAR AML-001 study

Maria Teresa Voso

S142

17:00–17:15

QuANTUM-First: Efficacy in newly diagnosed patients with fms-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy

Mikkael A. Sekeres

S144

17:30–17:45

Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort

Jorge Cortes

S265

16:30–16:45

Final long-term follow-up results of the RELAZA2 study: Azacitidine to treat measurable- residual disease in MDS and AML patients

Anne Sophie Kubasch


Sunday, June 16


Posters

P536

Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia study

Jorge Cortes

P540

Safety and activity of revumenib in combination with fludarabine/cytarabine (FLA) in patients with relapsed/refractory acute leukemias

Neerav Shukla

P560

Impact of TP53 mutations in patients with acute myeloid leukemia (AML) during oral azacitidine maintenance therapy: Outcomes from the QUAZAR AML-001 trial

Andrew H. Wei

P561

Gilteritinib plus venetoclax, low-dose cytarabine, and actinomycin D as first salvage therapy for relapsed or refractory FLT3 mutated acute myeloid leukemia

Andrius Žučenka

P565

FLAG regimen, combined with gemtuzumab (FLAG-GO) results in better optimal molecular response and outcomes, compared to combination with idarubicin (FLAG-IDA) in untreated core binding factor AML

Gautam Borthakur

P600

RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: Preliminary results from two ongoing studies

Dominik Chraniuk

P603

Phase II study of cladribine, idarubicin, and higher dose cytarabine (CLIA) in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML)

Tapan Kadia

P623

Reduced dose FLAG-mitoxantrone and low dose venetoclax induces deep remissions and high rate of transition to successful allogeneic stem cell transplantation in relapsed/refractory AML

Ahmad Ibrahim

P571

Real-world use of oral-azacitidine as maintenance therapy for acute myeloid leukemia in remission: Characteristics and outcomes of a French patient population

Christian Récher

P573

Prognostic relevance of TP53 mutations with or without concomitant complex karyotype in patients treated with CPX-351: Evidence from a large real-world Italian study.

Elisabetta Todisco

P1377

Long term efficacy results of the SIERRA trial: A phase 3 study of 131I-apamistamab-led allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, R/R AML

James M Foran

P1786

Pregnancy outcomes in patients with acute leukemia diagnosed at different gestation ages: A more than 30 years national research group for the treatment of acute leukemia experience

Vera Troitskaya

P1792

Time to hematologic recovery is a critical determinant of complete remission as a surrogate for overall survival after intensive chemotherapy for acute myeloid leukemia

Rithin Nedumannil

P1805

Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada

Brian Leber

P1810

Real-world use of first-line midostaurin in FLT3-mutated acute myeloid leukemia: A multicentric study from the Grupo Português de Leucemias Agudas

Joana Infante

P1818

The role of allo-HSCT in AML CR1 patients with MRD negativity after the first induction course

Elena Parovichnikova


EHA 2024 top abstracts

To download this document, click below.

Download here

More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox